Search

Your search keyword '"Kondo, Takayuki"' showing total 14 results
Start Over Author "Kondo, Takayuki" Journal journal of clinical oncology
14 results on '"Kondo, Takayuki"'

1. Phase Ib trial of durvalumab plus tremelimumab in combination with particle therapy in patients with advanced hepatocellular carcinoma with macrovascular invasion: DEPARTURE trial.

Author

Koroki, Keisuke, Ogasawara, Sadahisa, Makishima, Hirokazu, Wakatsuki, Masaru, Takahashi, Asahi, Kanzaki, Hiroaki, Kobayashi, Kazufumi, Inoue, Masanori, Kiyono, Soichiro, Nakamura, Masato, Kanogawa, Naoya, Kondo, Takayuki, Nakamoto, Shingo, Shiko, Yuki, Ozawa, Yoshihito, Inaba, Yosuke, Kurokawa, Tomoya, Hanaoka, Hideki, Yamada, Shigeru, and Kato, Naoya

Published
2024
Full Text
View/download PDF

2. Phase Ib trial of durvalumab plus tremelimumab in combination with particle therapy in advanced hepatocellular carcinoma patients with macrovascular invasion: DEPARTURE trial.

Author

Ogasawara, Sadahisa, primary, Koroki, Keisuke, additional, Makishima, Hirokazu, additional, Wakatsuki, Masaru, additional, Takahashi, Asahi, additional, Kanzaki, Hiroaki, additional, Kobayashi, Kazufumi, additional, Inoue, Masanori, additional, Kiyono, Soichiro, additional, Nakamura, Masato, additional, Kanogawa, Naoya, additional, Kondo, Takayuki, additional, Nakamoto, Shingo, additional, Shiko, Yuki, additional, Ozawa, Yoshihito, additional, Inaba, Yosuke, additional, Kurokawa, Tomoya, additional, Hanaoka, Hideki, additional, Yamada, Shigeru, additional, and Kato, Naoya, additional

Published
2024
Full Text
View/download PDF

3. Phase Ib trial of durvalumab plus tremelimumab in combination with particle radiotherapy in advanced hepatocellular carcinoma patients with macrovascular invasion: DEPARTURE trial

Author

Ogasawara, Sadahisa, Koroki, Keisuke, Hirokazu, Makishima, Masaru, Wakatsuki, Sakuma, Takafumi, Naoto, Fujita, Kanzaki, Hiroaki, Kobayashi, Kazufumi, Kiyono, Souichiro, Masato, Nakamura, Naoya, Kanogawa, Tomoko, Saitou, Kondo, Takayuki, Nakagawa, Ryo, Nakamoto, Shingo, Muroyama, Ryosuke, Chiba, Tetsuhiro, Hideki, Hanaoka, Hiroshi, Tsuji, and Kato, Naoya

Abstract

Background: Advanced hepatocellular carcinoma (HCC) with macrovascular invasion (MVI) has the worst prognosis among all HCC cases, due to its uniqueness of disease condition. Development of revolutionary therapeutic approaches to improve prognosis in these patients is an essential medical issue. A phase I/II trial demonstrated that treatment with durvalumab, an anti-programmed death-ligand 1 antibody, alone or in combination with tremelimumab, an anti-cytotoxic T-lymphocyte antigen 4 antibody, exhibited potential efficacy in patients with advanced HCC. Conversely, particle radiotherapy, including carbon-ion radiotherapy, has been shown to achieve unique dose distribution by delivering high-dose radiation to the target tumor while reducing the radiation dose to normal tissues due to its physical characteristics. Studies demonstrated that particle radiotherapy could achieve good local control in patients with HCC, including those with MVI. Additionally, particle radiotherapy as well as photon irradiation not only mediate localized tumor killing but also modify the tumor microenvironment, thereby potentiating the efficacy of immune checkpoint inhibitors. The DEPARTURE trial aims to evaluate whether treatment with durvalumab, alone or in combination with tremelimumab, plus particle radiotherapy is a safe and synergistically effective treatment in patients with advanced HCC and MVI. Methods: This is a phase Ib, multi-center, open-label, single-arm, investigator-initiated clinical trial to assess the safety of durvalumab monotherapy in combination with particle radiotherapy (Cohort A) and that of durvalumab plus tremelimumab in combination with particle radiotherapy (Cohort B) in advanced HCC patients with MVI who are ineligible for standard systemic therapy and Child–Pugh A liver disease. Cohort A will receive 1500 mg durvalumab every four weeks in principle. Cohort B will receive 1500 mg durvalumab every four weeks in principle and 300 mg tremelimumab only on day 1 of the first cycle. Carbon-ion radiotherapy will be administered after day 8 of the first cycle, following the first dose of either durvalumab or durvalumab plus tremelimumab on day 1. Dose prescription and fractionations are 60 Gy (RBE) in four fractions/1 week. Intrahepatic nodule with MVI is the target lesion for carbon-ion radiotherapy. Primary study endpoints are rates of all and severe adverse events including DLTs. Secondary endpoints include rates of overall survival, 6-month survival, objective response, and 6-month progression-free survival as well as time to progression.

Published
2022

4. Transition of the tumor microenvironment with clonal evolution of hepatocellular carcinoma.

Author

Kanzaki, Hiroaki, primary, Ogasawara, Sadahisa, additional, Sakuma, Takafumi, additional, Fujita, Naoto, additional, Kojima, Ryuta, additional, Koroki, Keisuke, additional, Kobayashi, Kazufumi, additional, Nakamura, Masato, additional, Kanogawa, Naoya, additional, Kiyono, Soichiro, additional, Kondo, Takayuki, additional, Saito, Tomoko, additional, Nakagawa, Ryo, additional, Nakamoto, Shingo, additional, Muroyama, Ryosuke, additional, Chiba, Tetsuhiro, additional, Ikeda, Junichiro, additional, Ohtsuka, Masayuki, additional, and Kato, Naoya, additional

Published
2022
Full Text
View/download PDF

5. Analysis of the tumor microenvironment in ineffective patients of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma.

Author

Kobayashi, Kazufumi, primary, Ogasawara, Sadahisa, additional, Ishino, Takamasa, additional, Unozawa, Hidemi, additional, Nakagawa, Miyuki, additional, Fujiwara, Kisako, additional, Sakuma, Takafumi, additional, Fujita, Naoto, additional, Kanzaki, Hiroaki, additional, Koroki, Keisuke, additional, Nakamura, Masato, additional, Kiyono, Soichiro, additional, Kanogawa, Naoya, additional, Kondo, Takayuki, additional, Saito, Tomoko, additional, Nakagawa, Ryo, additional, Nakamoto, Shingo, additional, Muroyama, Ryosuke, additional, Chiba, Tetsuhiro, additional, and Kato, Naoya, additional

Published
2022
Full Text
View/download PDF

6. Approaching the tumor microenvironment in patients with advanced hepatocellular carcinoma using needle biopsy samples.

Author

Kanzaki, Hiroaki, primary, Ogasawara, Sadahisa, additional, Koroki, Keisuke, additional, Kobayashi, Kazufumi, additional, Kiyono, Soichiro, additional, Kanogawa, Naoya, additional, Nakamura, Masato, additional, Saito, Tomoko, additional, Kondo, Takayuki, additional, Nakagawa, Ryo, additional, Suzuki, Eiichiro, additional, Nakamoto, Shingo, additional, Muroyama, Ryosuke, additional, Tawada, Akinobu, additional, Chiba, Tetsuhiro, additional, Arai, Makoto, additional, Ikeda, Junichiro, additional, Ohtsuka, Masayuki, additional, and Kato, Naoya, additional

Published
2021
Full Text
View/download PDF

7. Transition of molecular target agent therapy in advanced hepatocellular carcinoma: A multicenter, retrospective study.

Author

Kobayashi, Kazufumi, primary, Ogasawara, Sadahisa, additional, Takahashi, Aya, additional, Seko, Yuya, additional, Tsuchiya, Satoshi, additional, Iwai, Kenji, additional, Sato, Rui, additional, Watanabe, Shunji, additional, Koroki, Keisuke, additional, Kanzaki, Hiroaki, additional, Kanogawa, Naoya, additional, Kondo, Takayuki, additional, Suzuki, Eiichiro, additional, Chiba, Tetsuhiro, additional, Arai, Makoto, additional, Moriguchi, Michihisa, additional, Morimoto, Naoki, additional, Aramaki, Takeshi, additional, Itoh, Yoshito, additional, and Kato, Naoya, additional

Published
2021
Full Text
View/download PDF

8. Posttreatment after lenvatinib in patients with advanced hepatocellular carcinoma.

Author

Koroki, Keisuke, primary, Kanogawa, Naoya, additional, Maruta, Susumu, additional, Ogasawara, Sadahisa, additional, Obu, Masamichi, additional, Itokawa, Norio, additional, Inoue, Masanori, additional, Haga, Yuki, additional, Okabe, Shinichiro, additional, Seki, Atsuyoshi, additional, Atsukawa, Masanori, additional, Itobayashi, Ei, additional, Ito, Kenji, additional, Mizumoto, Hideaki, additional, Kobayashi, Kazufumi, additional, Kondo, Takayuki, additional, Suzuki, Eiichiro, additional, Chiba, Tetsuhiro, additional, Arai, Makoto, additional, and Kato, Naoya, additional

Published
2021
Full Text
View/download PDF

9. Phase I study of a new concept cancer vaccine composed artificial intelligence (AI)-designed shared-antigen peptides plus combined synergistically activating antigen-specific CTL reaction (CYT001) in patients with advanced hepatocellular carcinoma (CRESCENT 1).

Author

Ogasawara, Sadahisa, primary, Kanzaki, Hiroaki, additional, Koroki, Keisuke, additional, Kanayama, Kengo, additional, Maruta, Susumu, additional, Kobayashi, Kazufumi, additional, Kiyono, Souichiro, additional, Nakamura, Masato, additional, Kanogawa, Naoya, additional, Kondo, Takayuki, additional, Suzuki, Eiichiro, additional, Ooka, Yoshihiko, additional, Nakamoto, Shingo, additional, Tawada, Akinobu, additional, Chiba, Tetsuhiro, additional, Arai, Makoto, additional, Nakada, Hiroyuki, additional, Yamaguchi, Nobuko, additional, Hanaoka, Hideki, additional, and Kato, Naoya, additional

Published
2020
Full Text
View/download PDF

11. Muscle volume loss after the induction of first-line chemotherapy as a novel prognostic factor in metastatic colorectal cancer patients.

Author

Yoshikawa, Yusuke, primary, Okabayashi, Koji, additional, Hasegawa, Hirotoshi, additional, Tsuruta, Masashi, additional, Seishima, Ryo, additional, Takahashi, Hidena, additional, Yamada, Toru, additional, Matsui, Shimpei, additional, Kondo, Takayuki, additional, Shimada, Takehiro, additional, Matsuda, Mutsuhito, additional, Yahagi, Masashi, additional, Asada, Yusuke, additional, Sugiura, Kiyoaki, additional, Suzuki, Yoshiyuki, additional, Tajima, Yuki, additional, Nakadai, Junpei, additional, and Kitagawa, Yuko, additional

Published
2015
Full Text
View/download PDF

12. Impact of liver fibrosis on effects and adverse effects of unresectable colorectal cancer under first line chemotherapy including CPT-11.

Author

Yahagi, Masashi, primary, Tsuruta, Masashi, additional, Hasegawa, Hirotoshi, additional, Okabayashi, Koji, additional, Seishima, Ryo, additional, Takahashi, Hidena, additional, Matsui, Shimpei, additional, Yamada, Toru, additional, Kondo, Takayuki, additional, Shimada, Takehiro, additional, Matsuda, Mutsuhito, additional, Yoshikawa, Yusuke, additional, Asada, Yusuke, additional, Sugiura, Kiyoaki, additional, Suzuki, Yoshiyuki, additional, Tajima, Yuki, additional, Nakadai, Junpei, additional, and Kitagawa, Yuko, additional

Published
2015
Full Text
View/download PDF

13. The impact of hepatic fiblosis on the incidence of liver metastasis from colorectal cancer.

Author

Kondo, Takayuki, primary, Okabayashi, Koji, additional, Hasegawa, Hirotoshi, additional, Tsuruta, Masashi, additional, Seishima, Ryo, additional, Matsui, Shimpei, additional, Yamada, Toru, additional, Takahashi, Hidena, additional, Shimada, Takehiro, additional, Matsuda, Mutsuhito, additional, Yahagi, Masashi, additional, Yoshikawa, Yusuke, additional, Asada, Yusuke, additional, Sugiura, Kiyoaki, additional, Suzuki, Yoshiyuki, additional, Tajima, Yuki, additional, Nakadai, Junpei, additional, and Kitagawa, Yuko, additional

Published
2015
Full Text
View/download PDF

14. The impact of oral anticancer drugs on recurrence pattern after adjuvant chemotherapy in colorectal cancer patients.

Author

Shimada, Takehiro, primary, Tsuruta, Masashi, additional, Hasegawa, Hirotoshi, additional, Okabayashi, Koji, additional, Seishima, Ryo, additional, Takahashi, Hidena, additional, Matsui, Shimpei, additional, Yamada, Toru, additional, Kondo, Takayuki, additional, Matsuda, Mutsuhito, additional, Yahagi, Masashi, additional, Yoshikawa, Yusuke, additional, Asada, Yusuke, additional, Sugiura, Kiyoaki, additional, Suzuki, Yoshiyuki, additional, Tajima, Yuki, additional, Nakadai, Junpei, additional, and Kitagawa, Yuko, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results